Surgical Treatment of Talus Osteochondral Lesions with Platelet-Rich Plasma

D. R Muradyan; G. A Kesyan; A. N Levin; O. G Kesyan; A. V Mazur; I. M Kravec

doi:10.17816/vto201320346-50

N.N. Priorov Journal of Traumatology and Orthopedics ›› 2013, Vol. 20 ›› Issue (3) : 46 -50. DOI: 10.17816/vto201320346-50

Articles

research-article

Surgical Treatment of Talus Osteochondral Lesions with Platelet-Rich Plasma

Author information +

History +

PDF

Abstract

Wide application of cell therapy particularly platelet enriched plasma (PRP) in modern orthopaedics enabled to improved treatment results in certain orthopaedic diseases and injury consequences. Treatment results for 7 patients (2 men and 5 women) with osteochondral lesions of talus (OLT) are presented. Mean age of patients was 26 years, mean duration of disease — 4 years. By Brendt and Harty roentgenologic classification I—II degree of OLT was diagnosed in 1 and III—IV degree — in 6 patients. In all patients mosaic chondroplasty of talus with implantation of PRP gel was performed. Postoperatively mean AOFAS index raised from 53 to 92. Follow up period made up around 2 years.

Keywords

osteochondral lesions of talus / mosaic chondroplasty / osteochondritis dissecans / osteochondral autograft / platelet-rich plasma

Cite this article

Download citation ▾

D. R Muradyan, G. A Kesyan, A. N Levin, O. G Kesyan, A. V Mazur, I. M Kravec. Surgical Treatment of Talus Osteochondral Lesions with Platelet-Rich Plasma. N.N. Priorov Journal of Traumatology and Orthopedics, 2013, 20(3): 46-50 DOI:10.17816/vto201320346-50

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Berndt A.L., Harty M. Transcondylar fractures (osteochondritis dissecans) of the talus. J. Bone Joint Surg. Am. 1959; 41: 988-1020.

[2]	Clanton T.O., DeLee J.C. Osteochondritis dissecans. History, pathophysiology, and current treatment concepts. Clin. Orthop. Relat. Res. 1982; 167: 50-64.

[3]	Tol J.L., Struijs P.A., Bossuyt P.M., Verhagen R.A., van Dijk C.N. Treatment strategies in osteochondral defects of the talar dome: a systematic review. Foot Ankle Int. 2000; 21 (2): 119-26.

[4]	Pettine K.A., Morrey B.F. Osteochondral fractures of the talus. A long-term follow-up. J. Bone Joint Surg. Br. 1987; 69 (1): 89-92.

[5]	Zengerink M., Struijs P.A., Tol J.L., van Dijk C.N. Treatment of osteochondral lesions of the talus: a systematic review. Knee Surg. Sports Traumatol. Arthrosc. 2010; 18 (2): 238-46.

[6]

Anitua E, Sánchez M., Nurden A.T., Zalduendo M.M., de la Fuente M., Azofra J., Andía I. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology (Oxford). 2007; 46 (12): 1769-72.

[7]	Arnoczky S.P., Anderson L., Fanelli G., Sherwin S.W., Mishra A., Sgaglione N.A. The role of platelet-rich plasma in connective tissue repair. Orthopedics Today. 2009; 26: 29.

[8]

Кесян Г.А., Берченко Г.Н., Уразгильдеев Р.З., Микелаишвили Д.С. Сочетанное применение обогащенной тромбоцитами аутоплазмы и биокомпозиционного материала Коллапан в комплексном лечении больных с длительно несрастающимися переломами и ложными суставами длинных костей конечностей. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2011; 2: 26-32.

[9]	Микелаишвили Д.С. Применение аутотромбоцитарных факторов роста и коллапана при оперативном лечении диафизарных переломов: Автореф. дис.. канд. мед. наук. М., 2012.

[10]	Кесян Г.А., Берченко Г.Н., Уразгильдеев Р.З., Нахапетян Т.Г. Лечение разрывов ахиллова сухожилья. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2011; 4: 80-86.